Semnur Pharmaceuticals Reports $4.6 Million Net Loss and Increased Operating Expenses in Latest 10-Q

Semnur Pharmaceuticals, Inc., formerly known as Denali Capital Acquisition Corp., reported significant financial developments in its latest 10-Q filing for the quarter ending March 31, 2026. The company recorded a net loss of $4.6 million, compared to a loss of $665,000 in the same period last year, reflecting a substantial increase in operating expenses. Total operating expenses rose to $4.6 million from $665,000, driven primarily by a $1.1 million increase in research and development costs and a $2.8 million rise in general and administrative expenses. The increase in R&D expenses was largely attributed to higher personnel costs and clinical development activities related to the company's lead product candidate, SP-102.

The company’s cash and cash equivalents stood at $103,000 as of March 31, 2026, a notable increase from $20,000 at the end of the previous fiscal year. However, the accumulated deficit grew to $280.4 million, up from $275.8 million at the end of 2025. The increase in cash was primarily due to financing activities, which provided $2.8 million, largely from related-party loans, offset by cash used in operations amounting to $2.7 million. The company’s total liabilities increased to $27.3 million from $22.1 million, with current liabilities comprising a significant portion of this total.

Strategically, Semnur has been focused on advancing its clinical programs, particularly for SP-102, which is designed for the treatment of lumbosacral radicular pain. The company completed a pivotal Phase 3 study in March 2022 and initiated a second Phase 3 study in September 2025. The company’s operational metrics indicate a commitment to expanding its clinical trials, with research and development expenses expected to continue rising as the company progresses through its clinical development phases.

Despite these advancements, the company faces challenges in securing additional financing to support its operations and clinical trials. Semnur has indicated that it is exploring various financing options, including equity offerings and collaborations, to meet its liquidity needs. The company has expressed substantial doubt about its ability to continue as a going concern without additional funding, given its current cash position and ongoing operational losses. The outlook remains cautious as the company navigates the complexities of clinical development and seeks to establish itself in the competitive biopharmaceutical market.